← Back to Search

Other

CB-5339 for Myelodysplastic Syndrome

Phase 1
Waitlist Available
Research Sponsored by Cleave Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days
Awards & highlights

Study Summary

This trial is testing a new drug for people with certain types of leukemia or myelodysplastic syndrome.

Eligible Conditions
  • Myelodysplastic Syndrome
  • Acute Myeloid Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Define the MTD and/or RP2D and schedule for CB-5339
Therapeutic procedure
Secondary outcome measures
Accumulation ratio
Antitumor effects
Area under the plasma concentration time curve (AUC0-t)
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: CB-5339Experimental Treatment1 Intervention
Orally administered CB-5339
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CB-5339
2020
Completed Phase 1
~60

Find a Location

Who is running the clinical trial?

Cleave Therapeutics, Inc.Lead Sponsor
Scott HarrisStudy ChairCleave Therapeutics, Inc.

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what degree is CB-5339 hazardous to human health?

"Our experts at Power rated CB-5339 a 1 on the safety scale, due to this being an initial trial with limited evidence in terms of efficacy and safety."

Answered by AI

Is enrollment still open for the trial?

"Clinicaltrials.gov has confirmed that this trial is actively recruiting participants; the initial posting was on June 8th 2020, with a recent edit occurring on July 27th 2022."

Answered by AI

In what locations are this trial's efforts being conducted?

"At present, 8 medical centres are recruiting patients for this clinical trial. These locales span from Cleveland to Greenville and various other spots in-between; it is advisable to choose the nearest site of enrolment so as to abate any travel hardships."

Answered by AI

How many individuals are participating in the experiment?

"To launch the trial, 60 eligible individuals are needed. Cleave Therapeutics, Inc., is managing this study across multiple sites including Cleveland Clinic and Case Comprehensive Cancer Center in Ohio as well as Weill Cornel Medical Center in New york City."

Answered by AI
Recent research and studies
ChemMedChemJournal
Sulforaphane Is Synergistic with CB‐5083 and Inhibits Colony Formation of Cb‐5083‐resistant HCT116 Cells
Wang, Feng, Shan Li, William M. Rosencrans, Kai‐Wen Cheng, Gordon M. Stott, Barbara Mroczkowski, and Tsui‐Fen Chou. 2022. “Sulforaphane Is Synergistic with CB‐5083 and Inhibits Colony Formation of Cb‐5083‐resistant HCT116 Cells”. Chemmedchem. Wiley. doi:10.1002/cmdc.202200030.
clinicaltrials.govStudy
Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome
2020. "Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04402541.
~11 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top